Skip to content
2000
  1. Home
  2. A-Z Publications
  3. Current Genomics
  4. Volume 26, Issue 1
  5. Article
Volume 26, Issue 1
  • ISSN: 1389-2029
  • E-ISSN: 1875-5488

Abstract

Background

Lung adenocarcinoma, the predominant subtype of lung cancer, presents a significant challenge to public health due to its notably low five-year survival rate. Recent epidemiological data highlights a concerning trend: patients with pulmonary adenocarcinoma and comorbid diabetes exhibit substantially elevated mortality rates compared to those without diabetes, suggesting a potential link between hyperinsulinemia in diabetic individuals and accelerated progression of pulmonary adenocarcinoma. Insulin Receptor (IR) is a tyrosine-protein kinase on the cell surface, and its over-expression is considered the pathological hallmark of hyperinsulinemia in various cancer cell types. Research indicates that IR can translocate to the nucleus of lung adenocarcinoma cells to promote their proliferation, but its precise molecular targets remain unclear. This study aims to silence IRs in lung adenocarcinoma cells and identify key genes within the ERK pathway that may serve as potential molecular targets for intervention.

Methods

Gene expression data from lung adenocarcinoma and para cancer tissues were retrieved from the Gene Expression Omnibus (GEO) database and assessed through "pheatmap", GO annotation, KEGG analysis, R calculations, Cytoscape mapping, and Hub gene screening. Significant genes were visualized using the ggplot2 tool to compare expression patterns between the two groups. Additionally, survival analysis was performed using the R "survminer" and "survival" packages, along with the R "pathview" package for pathway visualization. Marker genes were identified and linked to relevant signaling pathways. Validation was conducted utilizing real-time quantitative polymerase chain reaction and immunoblotting assays in an A549 lung cancer cell model to determine the roles of these marker genes in associated signaling cascades.

Results

The study examined 58 lung adenocarcinoma samples and paired para-neoplastic tissues. Analysis of the GSE32863 dataset from GEO revealed 1040 differentially expressed genes, with 421 up-regulated and 619 down-regulated. Visualization of these differences identified 172 significant alterations, comprising 141 up-regulated and 31 down-regulated genes. Functional enrichment analysis using Gene Ontology (GO) revealed 56 molecular functions, 77 cellular components, and 816 biological processes. KEGG analysis identified 17 strongly enriched functions, including cytokine interactions and tumor necrosis factor signaling. Moreover, the ERK signaling pathway was associated with four Hub genes (FGFR4, ANGPT1, TEK, and IL1B) in cellular biological processes. Further validation demonstrated a positive correlation between IL-1B expression in the ERK signaling pathway and lung cancer through real-time fluorescence quantitative enzyme-linked reaction with immunoblotting assays.

Conclusion

In IR-silenced lung adenocarcinoma, the expression of the IL-1B gene exhibited a positive correlation with the ERK signaling pathway.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cg/10.2174/0113892029298721240627095839
2024-07-03
2024-12-26

  • From This Site

    /content/journals/cg/10.2174/0113892029298721240627095839
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. BrayF. FerlayJ. SoerjomataramI. SiegelR.L. TorreL.A. JemalA. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.CA Cancer J. Clin.201868639442410.3322/caac.2149230207593
     [Google Scholar]
  2. HerbstR.S. HeymachJ.V. LippmanS.M. Lung Cancer.N. Engl. J. Med.2008359131367138010.1056/NEJMra080271418815398
     [Google Scholar]
  3. SibilleA. PaulusA. MartinM. BourhabaM. BarthélemyN. RadermeckerM. CorhayJ.L. LouisR. DuysinxB. Management of non-small cell lung cancer.Rev. Med. Liege201570943244126638443
     [Google Scholar]
  4. HanahanD. WeinbergR.A. Hallmarks of cancer: The next generation.Cell2011144564667410.1016/j.cell.2011.02.01321376230
     [Google Scholar]
  5. GrivennikovS.I. GretenF.R. KarinM. Immunity, inflammation, and cancer.Cell2010140688389910.1016/j.cell.2010.01.02520303878
     [Google Scholar]
  6. WangX. LinY. Tumor necrosis factor and cancer, buddies or foes?Acta Pharmacol. Sin.200829111275128810.1111/j.1745‑7254.2008.00889.x18954521
     [Google Scholar]
  7. ApteR.N. VoronovE. Immunotherapeutic approaches of IL-1 neutralization in the tumor microenvironment.J. Leukoc. Biol.2017102229330610.1189/jlb.3MR1216‑523R28522598
     [Google Scholar]
  8. MantovaniA. DinarelloC.A. MolgoraM. GarlandaC. Interleukin-1 and related cytokines in the regulation of inflammation and immunity.Immunity201950477879510.1016/j.immuni.2019.03.01230995499
     [Google Scholar]
  9. WongC.C. BaumJ. SilvestroA. BesteM.T. Bharani-DharanB. XuS. WangY.A. WangX. PrescottM.F. KrajkovichL. DuganM. RidkerP.M. MartinA.M. SvenssonE.C. Inhibition of il1β by canakinumab may be effective against diverse molecular subtypes of lung cancer: An exploratory analysis of the CANTOS trial.Cancer Res.202080245597560510.1158/0008‑5472.CAN‑19‑317633023946
     [Google Scholar]
  10. XieH. ChenJ. LvX. ZhangL. WuJ. GeX. YangQ. ZhangD. ChenJ. Clinical Value of Serum and Exhaled Breath Condensate miR-186 and IL-1β Levels in Non-Small Cell Lung Cancer.Technol. Cancer Res. Treat.20201910.1177/153303382094749032851926
     [Google Scholar]
  11. BarrettJ.P. MinogueA.M. FalveyA. LynchM.A. Involvement of IGF-1 and Akt in M1/M2 activation state in bone marrow-derived macrophages.Exp. Cell Res.2015335225826810.1016/j.yexcr.2015.05.01526022664
     [Google Scholar]
  12. TopalianS.L. DrakeC.G. PardollD.M. Immune checkpoint blockade: A common denominator approach to cancer therapy.Cancer Cell201527445046110.1016/j.ccell.2015.03.00125858804
     [Google Scholar]
  13. SunY. WangY. ZhaoJ. GuM. GiscombeR. LefvertA.K. WangX. B7-H3 and B7-H4 expression in non-small-cell lung cancer.Lung Cancer200653214315110.1016/j.lungcan.2006.05.01216782226
     [Google Scholar]
  14. QiuR. MiaoT. LinL. WeiZ. Biological functions of nuclear-localized insulin receptor (IR) on A549 lung cancer cells.Endokrynol. Pol.202273112113034855195
     [Google Scholar]
  15. TavassolyI. GoldfarbJ. IyengarR. Systems biology primer: The basic methods and approaches.Essays Biochem.201862448750010.1042/EBC2018000330287586
     [Google Scholar]
  16. SabioG. DavisR.J. TNF and MAP kinase signalling pathways.Semin. Immunol.201426323724510.1016/j.smim.2014.02.00924647229
     [Google Scholar]
  17. EblenS.T. Extracellular-regulated kinases: Signaling from ras to erk substrates to control biological outcomes.Adv. Cancer Res.20181389914210.1016/bs.acr.2018.02.00429551131
     [Google Scholar]
  18. LuY. LiuB. LiuY. YuX. ChengG. Dual effects of active ERK in cancer: A potential target for enhancing radiosensitivity (Review).Oncol. Lett.2020202993100010.3892/ol.2020.1168432724338
     [Google Scholar]
  19. GilliesT.E. PargettM. SilvaJ.M. TeragawaC.K. McCormickF. AlbeckJ.G. Oncogenic mutant RAS signaling activity is rescaled by the ERK/MAPK pathway.Mol. Syst. Biol.20201610e951810.15252/msb.2020951833073539
     [Google Scholar]
  20. YangS. LiuG. Targeting the Ras/Raf/MEK/ERK pathway in hepatocellular carcinoma.Oncol. Lett.20171331041104710.3892/ol.2017.555728454211
     [Google Scholar]
  21. AnjumR. BlenisJ. The RSK family of kinases: Emerging roles in cellular signalling.Nat. Rev. Mol. Cell Biol.200891074775810.1038/nrm250918813292
     [Google Scholar]
  22. GuoY.J. PanW.W. LiuS.B. ShenZ.F. XuY. HuL.L. ERK/MAPK signalling pathway and tumorigenesis.Exp. Ther. Med.20201931997200732104259
     [Google Scholar]
  23. TangQ. WuJ. ZhengF. HannS.S. ChenY. Emodin increases expression of insulin-like growth factor binding protein 1 through activation of MEK/ERK/AMPKα and interaction of PPARγ and Sp1 in lung cancer.Cell. Physiol. Biochem.201741133935710.1159/00045628128214826
     [Google Scholar]
  24. SamatarA.A. PoulikakosP.I. Targeting RAS–ERK signalling in cancer: Promises and challenges.Nat. Rev. Drug Discov.2014131292894210.1038/nrd428125435214
     [Google Scholar]
  25. Pérez-RamírezC. AlnatshaA. Cañadas-GarreM. VillarE. Valdivia-BautistaJ. Faus-DáderM.J. Calleja-HernándezM.Á. Cytokine single-nucleotide polymorphisms and risk of non-small- cell lung cancer.Pharmacogenet. Genomics2017271243844410.1097/FPC.000000000000030728930110
     [Google Scholar]
  26. CareyA. EdwardsD.K.V EideC.A. NewellL. TraerE. MedeirosB.C. PollyeaD.A. DeiningerM.W. CollinsR.H. TynerJ.W. DrukerB.J. BagbyG.C. McWeeneyS.K. AgarwalA. Identification of interleukin-1 by functional screening as a key mediator of cellular expansion and disease progression in acute myeloid leukemia.Cell Rep.201718133204321810.1016/j.celrep.2017.03.01828355571
     [Google Scholar]
  27. CavalliG. ColafrancescoS. EmmiG. ImazioM. LopalcoG. MaggioM.C. SotaJ. DinarelloC.A. Interleukin 1α: a comprehensive review on the role of IL-1α in the pathogenesis and treatment of autoimmune and inflammatory diseases.Autoimmun. Rev.202120310276310.1016/j.autrev.2021.10276333482337
     [Google Scholar]
/content/journals/cg/10.2174/0113892029298721240627095839
Loading
Gene-knockdown Methods for Silencing Nuclear-localized Insulin Receptors in Lung Adenocarcinoma Cells: A Bioinformatics Approach
Curr. Genomics 26, 24 (2025); https://doi.org/10.2174/0113892029298721240627095839
/content/journals/cg/10.2174/0113892029298721240627095839
/content/journals/cg/10.2174/0113892029298721240627095839
Loading

Data & Media loading...


  • Article Type:     Research Article
Keyword(s): bioinformatics; ERK signaling pathway; genes; IL-1B; immunoblotting assays; Lung adenocarcinoma

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test